#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Initiating Antiretroviral Therapy for HIV at a Patient’s First Clinic Visit: The RapIT Randomized Controlled Trial


In the RapIT randomized controlled trial, Sydney Rosen and colleagues investigate whether accelerated initiation of antiretroviral therapy can improve viral suppression for HIV patients in South Africa.


Vyšlo v časopise: Initiating Antiretroviral Therapy for HIV at a Patient’s First Clinic Visit: The RapIT Randomized Controlled Trial. PLoS Med 13(5): e32767. doi:10.1371/journal.pmed.1002015
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002015

Souhrn

In the RapIT randomized controlled trial, Sydney Rosen and colleagues investigate whether accelerated initiation of antiretroviral therapy can improve viral suppression for HIV patients in South Africa.


Zdroje

1. Siedner MJ, Ng CK, Bassett I V, Katz IT, Bangsberg DR, Tsai AC. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002–2013: a meta-analysis. Clin Infect Dis. 2014; 60:1120–1127. doi: 10.1093/cid/ciu1137 25516189

2. Plazy M, Dray-Spira R, Orne-Gliemann J, Dabis F, Newell M- L. Continuum in HIV care from entry to ART initiation in rural KwaZulu-Natal, South Africa. Trop Med Int Health. 2014; 19:680–689. doi: 10.1111/tmi.12301 24654990

3. Clouse K, Pettifor AE, Maskew M, Bassett J, Van Rie A, Behets F, et al. Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2013; 62: 39–46.

4. Lahuerta M, Ue F, Hoffman S, Elul B, Kulkarni SG, Wu Y, et al. The problem of late ART initiation in Sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon? J Health Care Poor Underserved. 2013; 24: 359–383. doi: 10.1353/hpu.2013.0014 23377739

5. INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015; 373: 795–807. doi: 10.1056/NEJMoa1506816 26192873

6. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015.

7. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to ART care in sub-Saharan Africa: a systematic review. AIDS. 2012; 26: 2059–2067. doi: 10.1097/QAD.0b013e3283578b9b 22781227

8. Siedner MJ, Lankowski A, Haberer JE, Kembabazi A, Emenyonu N, Tsai AC, et al. Rethinking the “‘pre’” in pre-therapy counseling: no benefit of additional visits prior to therapy on adherence or viremia in Ugandans initiating ARVs. PLoS ONE. 2012; 7: e39894. doi: 10.1371/journal.pone.0039894 22761924

9. World Health Organization. Global update on the health sector response to HIV, 2014. Geneva: World Health Organization; 2014.

10. Ingle SM, May M, Uebel K, Timmerman V, Kotze E, Bachmann M, et al. Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS. 2010; 24: 2717–2725. doi: 10.1097/QAD.0b013e32833fb71f 20935554

11. Myer L, Zulliger R, Pienaar D. Diversity of patient preparation activities before initiation of antiretroviral therapy in Cape Town, South Africa. Trop Med Int Heal. 2012; 17: 972–977. doi: 10.1111/j.1365-3156.2012.03033.x

12. National Department of Health. The South African Antiretroviral Treatment Guideline 2013. Pretoria: National Department of Health; 2013.

13. Scott V, Zweigenthal V, Jennings K. Between HIV diagnosis and initiation of antiretroviral therapy: assessing the effectiveness of care for people living with HIV in the public primary care service in Cape Town, South Africa. Trop Med Int Heal. 2011; 16:1384–1391. doi: 10.1111/j.1365-3156.2011.02842.x

14. Gous N, Scott L, Potgieter J, Ntabeni L, Enslin S, Newman R, et al. Feasibility of performing multiple point of care testing for HIV anti-retroviral treatment initiation and monitoring from multiple or single fingersticks. PLoS ONE. 2013; 8: e85265. doi: 10.1371/journal.pone.0085265 24376873

15. Jani I V, Sitoe NE, Chongo PL, Alfai ER, Quevedo JI, Tobaiwa O, et al. Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing. AIDS. 2011; 25:807–812. doi: 10.1097/QAD.0b013e328344f424 21378535

16. Mnyani CN, McIntyre JA, Myer L. The reliability of point-of-care CD4 testing in identifying HIV-infected pregnant women eligible for antiretroviral therapy. J Acquir Immune Defic Syndr. 2012; 60: 260–264. doi: 10.1097/QAI.0b013e318256b651 22487589

17. Wade D, Daneau G, Aboud S, Vercauteren GH, Urassa WSK, Kestens L, et al. WHO multicenter evaluation of FACSCount CD4 and Pima CD4 t-cell count systems : instrument performance and misclassification of HIV-infected patients. J Acquir Immune Defic Syndr. 2014; 66:98–107.

18. Scott LE, Campbell J, Westerman L, Kestens L, Vojnov L, Kohastsu L, et al. A meta-analysis of the performance of the Pima CD4 for point of care testing. BMC Med. 2015; 13:168. doi: 10.1186/s12916-015-0396-2 26208867

19. Meyer-Rath G, Schnippel K, Long L, Macleod W, Sanne I, Stevens W, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS ONE. 2012; 7:e36966. 10.1371/journal.pone.0036966. doi: 10.1371/journal.pone.0036966 22693561

20. UNITAID. Tuberculosis diagnostics technology and market landscape. Geneva: UNITAID; 2013.

21. Fox MP, Maskew M, MacPhail A. Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. International Journal of Epidemiology. 2013; 42:430–439. doi: 10.1093/ije/dys029 22434860

22. Hoffmann CJ, Lewis JJ, Dowdy DW, Fielding KL, Grant AD, Martinson N, et al. Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model. J Acquir Immune Defic Syndr. 2013; 63:105–111. doi: 10.1097/QAI.0b013e3182893fb4 23392457

23. Jani I V, Sitoe NE, Alfai ER, Chongo PL, Quevedo JI, Rocha BM, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: An observational cohort study. Lancet. 2011; 378:1572–1579. doi: 10.1016/S0140-6736(11)61052-0 21951656

24. Burtle D, Welfare W, Elden S, Mamvura C, Vandelanotte J, Petherick E, et al. Introduction and evaluation of a “pre-ART care” service in Swaziland: an operational research study. BMJ Open. 2012; 2:e000195. doi: 10.1136/bmjopen-2011-000195

25. Black S, Zulliger R, Myer L, Marcus R, Jeneker S, Hons BA, et al. Safety, feasibility and efficacy of a rapid ART initiation in pregnancy pilot programme in Cape Town, South Africa. S Afr Med J. 2013; 103:557–562. doi: 10.7196/SAMJ.6565 23885739

26. Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015; 385:2173–2182. doi: 10.1016/S0140-6736(15)60164-7 25765698

27. Clouse K, Page-Shipp L, Dansey H, Moatlhodi B, Scott L, Bassett J, et al. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012; 102:805–807. doi: 10.7196/SAMJ.5851 23034211

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2016 Číslo 5
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Aktuální možnosti diagnostiky a léčby litiáz
nový kurz
Autori: MUDr. Tomáš Ürge, PhD.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#